AZD-103 is part of an emerging class of disease-modifying agents that have the potential to both reduce disease progression and improve symptoms such as cognitive function. This unique class of therapeutics is expected to provide significant advantages over the current products on the market, which only treat disease symptoms.
“The initiation of a phase I clinical investigation of one of the most promising disease modifying drug candidates, AZD-103, represents a major step forward for the company and offers a new hope for millions of Alzheimer’s patients and their families seeking relief from this devastating disease,” said Dr Tony Cruz, chairman and CEO of Transition.
The objective of this phase I trial is to evaluate the pharmacokinetics, safety and tolerability of escalating oral doses of AZD-103 in 12 healthy volunteers.